Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage

Breast Cancer Research and Treatment

Volumn 62, Issue 3, 2000, Pages 223-235

  Gewirtz, D A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adriamycin; Apoptosis; DNA damage; Growth arrest; Ionizing radiation

Indexed keywords

CAMPTOTHECIN; CASPASE 3; CERAMIDE; DOXORUBICIN; FAS ANTIGEN; GYRASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; IONIZING RADIATION; MUTANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SENESCENCE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; RADIATION, IONIZING;

EID: 0033761072     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006414422919     Document Type: Article

References (189)

1. Lack of cell cycle regulation of telomerase activity in human cells
2. Telomerases, senescence and cellular radiation response
3. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs
4. Delayed reproductive cell death in xirradiated Chinese hamster ovary cells
5. Review: Ionizing radiation-induced cell death
6. Apoptosis and mitotic cell death: Their relative contributions to normal tissue and tumor radiation response
7. Apoptosis, p53 and tumor cell sensitivity to anticancer agents
8. A matter of life and cell death
9. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
10. p53 Dependent apoptosis modulates the cytotoxicity of anticancer agents
11. p53 Status and the efficacy of cancer therapy in vivo
12. p53 Gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents
13. Role of p53 mutations in the radiosensitivity status of tumor cells
14. p53 Gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin
15. p53 Gene status modulates the chemosensitivity of non-small cell lung cancer cells
16. Repair of DNA double strand breaks and radiosensitivity to killing in an isogenic group of p53 mutant cell lines
17. No association between radiosensitivity and TP53 status, G1 arrest or protein levels of p53, myc, ras or raf in human melanoma lines
18. Tumor radiosensitivity and apoptosis
19. Apoptosis and drug response
20. Radiosensitization of HL-60 human leukemic cells by bryostatin-1 in the absence of increased DNA fragmentation or apoptotic cell death
21. Potentiation of taxol-induced apoptosis and antiproliferative effects in human myeloid leukemic cells (U937) by bryostatin-l
22. Radiation induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53
23. Expression of p53, p21, Bcl-2, Bax, Bcl-x and Bak in radiation-induced apoptosis in testicular germ cell tumor lines
24. Role of a mutant p53 protein in apoptosis: Characterization of a function independent of transcriptional trans-activation
25. Participation of p53 protein in the cellular response to DNA damage
26. Effect of cell cycle, wild-type p53 and DNA damage on p21(waf1/cip1) expression in human breast epithelial cells
27. ATM selectively regulates distinct p53 dependent cell cycle checkpoint and apoptotic pathways
28. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53
29. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK 4a locus deletion impairs both the Rb and tumor suppressor pathways
30. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
31. Induction of apoptosis in fibroblasts by c-myc protein
32. Mediation of myc induced apoptosis by p53
33. p53 and E2F-1 cooperate to mediate apoptosis
34. Distinct roles for E2F proteins in cell growth control and apoptosis
35. Myc signaling via the ARF tumor suppressor regulates p53 dependent apoptosis and immortalization
36. P14ARF links the tumor suppressors Rb and p53
37. Tumor suppressors p53 is a regulator of bcl-2 and bax expression in vitro and in vivo
38. Bcl-2 heterodimerizes in vivo with a homologue Bax that accelerates programmed cell death
39. The binding properties and biological activities of Bcl-2 and bax in cells exposed to apoptotic stimuli
40. Inactivation of Bcl-2 by phosphorylation
41. Raf/bcl-2 phosphorylation: A step from microtubule damage to cell death
42. bcl-x, a bcl- 2 Related gene that functions as a dominant regulator of apoptotic cell death
43. 1 protects cancer cells from p53-mediated apoptosis
44. 1 and Bcl-2 displaces Bax and promotes cell death
45. Bcl-2 family proteins
46. Mitochondrial permeability transition is a central co-ordinating event of apoptosis
47. 1 regulates the membrane potential and volume homeostatisis of mitochondria
48. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis
49. Conversion of Bcl-2 to a Bax like death effector by caspases
50. Caspases: The executioners of apoptosis
51. Apaf, a human protein analog to C elegans CED-4, participates in cytochrome c dependent activation of caspase 3
52. Cytochrome c and dATP dependent formation of Apas1/caspase 9 complex
53. Caspase 9, Bcl-xl and Apaf 1 form a ternary complex
54. DFF - A heterodimeric protein that functions downstream of caspase 3 to trigger DNA fragmentation
55. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-2
56. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug resistant cells
57. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells
58. Doxorubicin-induced DNA degradation in murine thymocytes
59. Radiation response of mouse lymphoma and melanoma cells Part II. Apoptotic death is shown in all cell lines examined
60. Ceramide synthase mediates daunorubicin-induced apoptosis an alternative mechanism for generating death signals
61. Daunorubicin-induced apoptosis: Triggering of ceramide generation through sphingomyelin hydrolysis
62. Apoptotic death in epithelial cells: Cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation
63. Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin
64. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline
65. Normal p53 status and function despite the development of drug resistance in human breast cancer cells
66. Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin
67. Overexpression of Bax sensitizes human breast cancer MCF-7 cells to radiation induced apoptosis
68. Paclitaxel-induced apoptosis in MCF-7 breast cancer cells
69. The influence of ionizing radiation on proliferation, c-myc expression and the induction of apoptotic cell death in two breast tumor cell lines differing in p53 status
70. Factors affecting topotecan induced programmed cell death: Adhesion protects cells from apoptosis and impairs cleavage of poly(ADP)-ribose-polymerase
71. Promotion of apoptosis in response to radiation in p53 wild-type human breast tumor cells by the vitamin D3 analog EB 1089
72. Eb 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells
73. The cell death response to gamma-irradiation is enhanced by a neuroleptic drug, pimozide
74. A sensescence like phenotype distinguishes tumor cells that undergo terminal proliferation after exposure to anticancer drugs
75. Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cacer cell line MCF-7
76. P53 mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells
77. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA damaging agents
78. Scatter factor protects ephitelial and carcinoma cells against apoptosis induced by DNA-damaging agents
79. Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells
80. Chemotherapy and cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells altered by osteoclast growth factors
81. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
82. Disruption of p53 in human cancer cells alters the response to therapeutic agents
83. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide
84. Caspase activation in MCF-7 cells responding to etoposide treatment
85. MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormonal withdrawal and DNA damage
86. Overexpression of Bcl-xs sensitizes MCF-7 cells to chemotherapy induced apoptosis
87. Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy
88. Ca/Mg dependent endonuclease activation is an early event in VP-16 induced apoptosis of human breast MCF-7 cells in vitro
89. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanisms of cell killing by camptothecin
90. Induction of apoptosis in MCF-7: WS8 breast cancer cells by beta-lapachone
91. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen: Multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways
92. Upregulation of p21waf1/cip1 in human breast cancer cell lines MCF-7 ad MDA-MB468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways
93. Comparison of methods based on annexin V binding, DNA content or TUNEL for evaluating cell death in HL60 and adherent MCF-7 cell
94. Cell death: Programmed, apoptosis, necrosis or other?
95. p53 Dependent and p53 independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin
96. Protein synthesis dependent cytoplasmic translocation of p53 protein after serum stimulation of growth arrested cells
97. Effect of cell cycle, wild-type p53 and DNA damage on p21(waf1/cip1) expression in human breast epithelial cells
98. Mechanisms of regulations of waf1/cip 1 gene expression in human breast carcinoma and role of p53 dependent and independent signal transduction pathways
99. Ionizing radiation and teniposide increase p21(waf1/cip1) and promote Rb dephosphorylation but fail to suppress E2F activity in MCF-7 breast tumor cells
100. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
101. 14-3-3σ Is required to prevent mitotic catastrophe after DNA damage
102. The E2F transcription factor is a cellular target for the Rb protein
103. Retinoblastoma protein switches the E2F site from positive to negative element
104. The retinoblastoma tumor suppressor protein
105. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins
106. The role of E2F in the mammalian cell cycle
107. Correlation between E2F-1 requirement in the S phase and E2F-1 transactivation of cell cycle related genes in human cells
108. The retinoblastoma protein and cell cycle control
109. Role for E2F in DNA damage induced entry of cells into S phase
110. Transcriptional activation by p53 but not induction of the p21 gene, is essential for oncogene mediated apoptosis
111. The apoptotic and transcriptional transactivation activities of p53 can be dissociated
112. p21(waf1/Cip1) Protects against p53-mediated apoptosis of human melanoma cells
113. p53 Expression overcomes p21(waf1/cip1) - Mediated G1 arrest and induces apoptosis in human cancer cells
114. Expression of the bcl-2 gene family in normal and malignant breast tissue: Low Bax-alpha expression in tumor cells correlates with resistance towards apoptosis
115. Expression of multiple apoptosis regulatory genes in human breast cancer cell lines and primary tumors
116. Involvement of microtubules in the regulation of bcl-2 phosphorylation and apoptosis through cyclic AMP dependent protein kinase
117. Induction of the death promoting gene Bax sensitizes cultured breast cancer cells to drug-induced apoptosis
118. Caspase 3 is required for DNA fragmentation and morphological changes associated with apoptosis
119. Apoptosis induced by vitamin D compounds is breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53
120. TN and cancer therapy induce apoptosis: Potentiation by inhibition of NF kappa B
121. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor induced apoptosis and activation of nuclear transcription factor kB and activated protein-1
122. Ikappa B alpha overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor kappa B activation
123. Suppression of tumor-necrosis factor induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappa B control
124. Impaired regulation of nuclear factor kappa B results in apoptosis induced by gamma irradiation
125. The c-IAP-1 and cIAP-2 proteins are direct inhibitors of specific caspases
126. Human IAP like protein regulates programmed cell death downstream of Bcl-xl and cytochrome c
127. Aberrant nuclear factor kappa B/Rel expression and the pathogenesis of breast cancer
128. Bcl-2 activates the transcription factor NfkappaB through the degradation of the cytoplasmic inhibitor IkappaB alpha
129. Insulin-like growth factors in breast cancer
130. Insulin-like growth factor binding protein (IGFBP)-3 protease activity secreted by MCF-7 breast cancer cells: Inhibition by IGFs does not require IGF-IGFBP interaction
131. Insulin-like growth factor binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF dependent manner
132. Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein 3 (IGFBP-3) in breast cancer cells
133. The PI3 kinase/Akt signaling pathway delivers an anti-apoptotic signal
134. Antiapopototic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3 kinase and Akt
135. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3' kinase and mitogen activated protein kinase pathways
136. Akt phosphorylation of BAD couples survival signals to the cell intrinsic death machinery
137. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen activated protein kinase pathway
138. Insulin-like growth factor binding protein 3 mediated retinoic acid and transforming growth factor beta 2 induced growth inhibition in human breast cancer cells
139. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells
140. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogs is associated with increased expression of insulin-like growth factor binding protein 3
141. Insulin-like growth factor binding protein-3 induces apoptosis in MCF-7 breast cancer cells
142. Insulin-like growth factor-1 inhibits cell death induced by anticancer drugs in the MCF-7 cells: Involvement of growth factors in drug resistance
143. Insulin-like growth factor (IGF-1) alters drug sensitivity of HBL-100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs
144. Role of AKTl in 17β-estradiol and insulin-like growth factor 1 (IGF-1) dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells
145. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis
146. The cellular response to oxidative stress: Influence of mitogen activated protein kinase signalling pathways on cell survival
147. Inhibition of the MAPK pathway abrogates Bcl-2 mediated survival of leukemia cells after exposure to low dose radiation
148. Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK-1 activation and enhance radiation toxicity of human mammary carcinoma cells
149. Roles for basal and stimulated p21 Cip1/waf1/MDA6 expression and mitogen activated protein kinase signaling in radiation induced cell cycle checkpoint control in carcinoma cells
150. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis
151. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis
152. Lack of ceramide generation in TF-1 human myeloid leukemic cells resistants to ionizing radiation
153. Loss of ceramide production confers resistance to raadiation-induced apoptosis
154. Expression of glucosylceramide synthetase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells
155. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics
156. Cytotoxic drugs and the CD95 pathway
157. Involvement of the CD95 (APO/FAS) receptor ligand system in drug-induced apoptosis in leukemia cells
158. The CD95 (APO/FAS) system mediates drug-induced apoptosis in neuroblastoma cells
159. A fas-dependent component in 5-fluorouracil/leucovorin induced cytotoxicity in colon carcinoma cells
160. Selection for drug resistance results in resistance to Fas-mediated apoptosis
161. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system
162. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity
163. The role of p53 and the CD95 (APO1/FAS) death system in chemotherapy induced apoptosis
164. Fractionatedgamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95
165. Fas ligand independent, FADD mediated activation of the Fas death pathway by anticancer drugs
166. Vitamin E succinate induces Fasmediated apoptosis in estrogen receptor negative human breast tumor cells
167. Fas expression and function in normal and malignant breast cancer cells
168. Activation of CD95 (APO1/Fas) signaling by ceramide mediated cancer thereapy apoptosis
169. Differential induction of apoptosis in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2 A
170. Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumor regression
171. Effects of all-trans retinoic acid and 13-cis-retinoic acid on breast cancer cell lines: Growth inhibition and apoptosis induction
172. A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells
173. EGF-induced programmed cell death of human mammary carcinoma MDA-MB468 cells is preceded by activation of AP-1
174. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells
175. Rar alpha antagonist RO 41-5253 inhibits proliferation and induces apoptosis in breast cancer cell lines
176. Specific p53 mutations are associated with de vovo resistance to doxorubicin in breast cancer patients
177. Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients
178. Reduced apoptosis and proliferations and increased Bcl-2 in residual breast cancer following preoperative chemotherapy
179. Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis
180. Loss of p21waf1/cip 1 sensitizes tumors to radiation by an apoptosis independent mechanism
181. p53 Status affects the rate of onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-myc
182. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival
183. Cell-cycle arrest versus cell death in cancer therapy
184. Remission of human breast cancer xenografts in therapy with humanized monoclonal antibody to Her-2 receptor and DNA reactive drugs
185. Recombinant humanize Anti Her-2 antibody enhances the antitumor activity of paclitaxel and doxorubicin against Her2/neu overexpressing human breast cancer xenografts
186. Apoptosis and chemotherapy resistance
187. Genomic instability induced by ionizing radiation
188. Relaxed cell cycle arrests and propagation of unrepaired chromosomal damage in cancer lines with wild type p53